Studies have shown that GLP-1 agonists have promising potential to act solely as weight loss medications in those with or without T2DM, due to their ability to slow gastric emptying and increase satiety.1,4–6 While at one time these medications were used off-label as weight loss medications, the compelling clinical trial evidence led to recent Food Drug Administration approval of these drugs for the purpose of chronic weight management in those who are overweight or obese.5,6 Evidence supports the use of the GLP-1 agonists semaglutide and liraglutide for this purpose. The gene discussed is GCG; the disease is type 2 diabetes mellitus.